This is a working overview of secretagogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-15 and is reviewed periodically as new material appears.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
=== Solar heating === Solar heating has the ability to erode a CAD event by heating the surface in the absence of a thick overcast. However, even a shallow stratus layer during the cold season can render solar heating ineffective. During breaks of overcast for the warm season, absorption of solar radiation at the surface warms the cold dome, once again lowering the Richardson number and promoting mixing.
The name and coat of arms of the present state go back to the Germanic tribe of Saxons. During the Migration Period some of the Saxon peoples left their homeland in Holstein about the 3rd century and pushed southwards over the Elbe, where they expanded into the sparsely populated regions in the rest of the lowlands, in present-day Northwest Germany and the northeastern part of what is now the Netherlands. From about the 7th century the Saxons had occupied a settlement area that roughly corresponds to the present state of Lower Saxony, of Westphalia and a number of areas to the east, for example, in what is now west and north Saxony-Anhalt. The land of the Saxons was divided into about 60 Gaue. The Frisians had not moved into this region; for centuries they preserved their independence in the most northwesterly region of the present-day Lower Saxon territory. The original language of the folk in the area of Old Saxony was West Low German, one of the varieties of language in the Low German dialect group.
== Pharmacokinetics == Many drugs follow the multi-compartment model. In other words, a drug may have a preference for a particular body compartment which will result in the majority of that drug to ultimately settle in that particular compartment. For highly polar drugs very little will be in the tissues of the body For highly lipophilic drugs majority of drug will be located in body tissues Initially, because the drug is given intravenously, the drug will distribute to the central compartment (i.e. circulation system). The drug (e.g. lipophilic drug) will move out of the central compartment and move into the peripheral compartments The movement from one compartment to another is influenced by passive diffusion (Moves from an area of high concentration to one with low concentration) A drug like fentanyl is very fat soluble. Initial doses ‘wear off’ relatively quickly because the drug redistributes to adipose tissue. However, if the infusion is ongoing then the peripheral compartment (body tissue) will have a large store of fentanyl The duration of infusion determines whether or not steady state was reached Once a drug enters the body, elimination and distribution begins. Initially the drug present in central compartment (i.e. circulation system) is being distributed into the tissues, and being eliminated At steady state, the concentration of free drug in the central compartment (i.e. circulation system) is equal to the concentration of free drug in the peripheral compartment (i.e.
If the reaction is more complicated, then the output is not uniquely determined by the RTD. It also depends on the degree of micromixing, the mixing between molecules that entered at different times. If there is no mixing, the system is said to be completely segregated, and the output can be given in the form
== Playwrights == Peter Barnes, playwright Steven Berkoff, playwright, actor, author, and theatre director Ashley Blaker, comedian and television producer; writer for TV and radio and longtime collaborator with Matt Lucas: was producer of Little Britain and Rock Profile. Lucas described Blaker as "the UK's only Orthodox comedian". Blaker's Off-Broadway show, Strictly Unorthodox, opened in 2017 at The Theater Center. and his second Off-Broadway show, Goy Friendly opened in February 2020, at SoHo Playhouse. Ben Elton (born 3 May 1959) comedian, actor, author, playwright, lyricist and director; was a part of London's alternative comedy movement of the 1980s and writer on the sitcoms The Young Ones and Blackadder, as well as stand-up comedian on stage and television; style in the 1980s was left-wing political satire; Elton is cousin of singer Olivia Newton-John; Elton's father is from a German-Jewish family and Elton's mother, who was raised in the Church of England, is of English background; has published 17 novels and written numerous rock operas and musicals. Ronald Harwood (né Horwitz; 9 November 1934 – 8 September 2020) was a South African Jewish -born British author, playwright, and screenwriter, best known for his plays for the British stage as well as the screenplays for The Dresser (for which he was nominated for an Oscar) and The Pianist, for which he won the 2003 Academy Award for Best Adapted Screenplay. He was nominated for the Best Adapted Screenplay Oscar for The Diving Bell and the Butterfly (2007); cousin of Antony Sher.
Sources: en.wikipedia.org
2015: Edgar Savisaar, Estonian politician, had his right leg amputated. He got the disease during a trip to Thailand. 2018: Alex Smith, an American football quarterback for the Washington Football Team of the National Football League (NFL), contracted the disease after being injured during a game. He suffered an open compound fracture in his lower leg, which became infected. Smith narrowly avoided amputation and eventually returned to playing professional football in October 2020. Smith's injury and recovery is the subject of the ESPN documentary E60 Presents: Project 11. 2019: OG Maco contracted NF after an untreated rash. 2021: Irish actor Barry Keoghan revealed in 2024 that he contracted NF shortly before filming The Banshees of Inisherin and nearly had his arm amputated.
=== Mechanical engineer === In 1912, Jones moved to Hallock, Minnesota, where he worked as a mechanic on a 50,000-acre (200 km2) farm. The farm was owned by James J. Hill, who was also owner of the Great Northern Railroad. Jones' proximity to Hill and the railroad facilitated his education in electricity and steam locomotive engines. Jones lived there for more than 20 years and would later say in a newspaper article that Hallock was a place "where a man … [was] judged more on his character and ability than on the color of his skin." He was locally known as "Casey" due to a remark by a railroad engineer he met while working at Hill Farm (see also Casey Jones). Jones received his engineering license at age 20. He later upgraded his license to the highest grade.
Another emerging and promising application of freeze casting is the production of porous foams for green hydrogen generation through advanced thermochemical processes like Chemical Loop Combustion (CLC) and the Steam Iron Process (SIP). These processes leverage the unique properties of porous metal structures, such as optimized reaction kinetics, enhanced thermal efficiency, and sustainability. In Chemical Loop Combustion (CLC), foams made from materials like iron oxides act as oxygen carriers, enabling fuel combustion without direct air contact, separating CO2 for capture while producing high-purity hydrogen. Similarly, in Steam Iron Process (SIP), dendritic pore structures ensure efficient water vapor distribution and maximize hydrogen yield. The precise control over porosity and thermal properties afforded by freeze casting, along with the use of eco-friendly solvents like camphene, positions these foams as a vital innovation for scalable and sustainable hydrogen production, contributing to the fight against climate change.
=== Cardioprotection against Ischemic injury === JM Downey was the first to introduce the role of PKC in cardioprotection against ischemia-reperfusion injury in 1994,; this seminal idea stimulated a series of studies which examined the different isoforms of PKC. PKCε has been demonstrated to be a central player in preconditioning in multiple independent studies, with its best known actions at cardiac mitochondria. It was first demonstrated by Ping et al. that in five distinct preconditioning regimens in conscious rabbits, the epsilon isoform of PKC specifically translocated from the cytosolic to particulate fraction. This finding was validated by multiple independent studies occurring shortly thereafter, and has since been observed in multiple animal models and human tissue, as well as in studies employing transgenesis and PKCε activators/inhibitors. Mitochondrial targets of PKCε involved in cardioprotection have been actively pursued, since the translocation of PKCε to mitochondria following protective stimuli is one of the most well-accepted cardioprotective paradigms. PKCε has been shown to target and phosphorylate alcohol dehydrogenase 2 (ALDH2) following preconditioning stimuli, which increased the activity of ALDH2 and reduced infarct size. Moreover, PKCε interacts with cytochrome c oxidase subunit IV (COIV), and preconditioning stimuli evoked phosphorylation of COIV and stabilization of COIV protein and activity.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.